EP300 and chronic myelogenous leukemia, BCR-ABL1 positive: β-catenin physically interact with CREB-binding protein (CBP)/P300, identified as transcriptional coactivators in cell differentiation, indicating that CBP inhibition may be a new strategy for CML therapy [131].